Assessing the safety and effectiveness of the BariClip device in the treatment of severe obesity in Jordan

ISRCTN ISRCTN98465849
DOI https://doi.org/10.1186/ISRCTN98465849
Secondary identifying numbers GBMC 00001
Submission date
29/12/2022
Registration date
16/02/2023
Last edited
14/02/2023
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Obesity and its associated disorders such as type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular (heart) disease have reached pandemic proportions worldwide. Conventional medical care offers only limited results, both in weight reduction and associated disorders. Bariatric surgery allows a significant and sustained weight loss in the majority of cases, a decrease in the frequency and severity of associated disorders, including type 2 diabetes, and decreased risk of death including from cardiovascular diseases. However, it requires a major abdominal surgery associated with an estimated 5% significant risk of illness after surgery and an average postoperative risk of death estimated at 0.3%. A new device has been developed which is basically a nonadjustable vertical clip. This device, the BariClip, placed parallel to the lesser curvature of the stomach, aims to restrict food intake without changing the stomach or small bowel anatomy, requires no stapling, causes no malabsorption, does not require any maintenance or surveillance, and is reversible. The aim of this study is to assess the safety and effectiveness of this device as a treatment for obesity and its related disorders.

Who can participate?
Adults between the age of 18 and 65 years with a BMI >40 kg/m² or a BMI >30 kg/m² with at least one associated disorder and a history of obesity for at least 5 years with failed dieting attempts

What does the study involve?
Participants will undergo a laparoscopic clip gastroplasty with the use of the BariClip device and will be followed up for a total of 60 months. Weight loss will be assessed at 1, 3, 6, 12, 18, 24, 36, 48 and 60 months after implantation, and routine labs and imaging will be conducted on day 1, at 3 months, and at 24 months.

What are the possible benefits and risks of participating?
The clip offers a treatment for obesity and its associated disorders that causes fewer complications and is reversible.

Where is the study run from?
Jordan Hospital (Jordan)

When is the study starting and how long is it expected to run for?
December 2022 to June 2028

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Ashraf Haddad, Ashraf.haddad@gbmc-jo.com

Contact information

Dr Ashraf Haddad
Principal Investigator

Gastrointestinal Bariatric and Metabolic Center (GBMC)
Jordan Hospital
Amman
11152
Jordan

Phone +962 (0)7 9557 2195
Email Ashraf.haddad@gbmc-jo.com
Dr Ashraf Haddad
Scientific

Gastrointestinal Bariatric and Metabolic Center (GBMC)
Jordan Hospital
Amman
11152
Jordan

Phone +962 (0)7 9557 2195
Email Ashraf.haddad@gbmc-jo.com
Dr Ashraf Haddad
Public

Gastrointestinal Bariatric and Metabolic Center (GBMC)
Jordan Hospital
Amman
11152
Jordan

Phone +962 (0)7 9557 2195
Email Ashraf.haddad@gbmc-jo.com

Study information

Study designMulticenter prospective single-arm clinical trial
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a participant information sheet
Scientific titleAssessing weight loss, adverse events, and resolution of comorbid conditions associated with the use of the BariClip device in adult patients with severe obesity in Jordan
Study acronymBariClip-Jo
Study objectivesThe BariClip device provides a reversible alternative to sleeve gastrectomy that is just as efficacious in terms of weight loss.
Ethics approval(s)1. Approved 31/01/2023, the Institutional Review Boards of Jordan Hospital (Queen Nour Street, PO Box 520248, Amman, Jordan; +962 (0)795528298; jorhos@jordan-hospital.com, saeb.hammoudi@gmail.com), ref: not applicable
2. Approved 11/02/2023, Al Khalidi Hospital & Medical Center (39 Ibn Khaldoun Street, 4th Circle Jebal Amman, Jordan; +962 (0)795598687; Dr.Nael.kaf@khmc.jo), ref: KHMC/22/R/93
Health condition(s) or problem(s) studiedObesity and its associated disorders
InterventionLaparoscopic vertical clip gastroplasty with the BariClip device.

In the procedure, the clip is placed parallel to lesser curvature to separate the stomach into a restricted medial segment where food passes and an excluded larger lateral gastric segment. It aims to restrict oral intake without changing the gastric or small bowel anatomy, requires no stapling, causes no malabsorption, does not require any maintenance or surveillance, and is reversible.
Intervention typeDevice
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)BariClip
Primary outcome measurePercent Excess Weight Loss (%EWL) defined as weight loss divided by baseline excess weight. Excess weight will be determined from ideal body weight based on a BMI of 24.9 for normal adults (Center for Disease Control [CDC]) at 1, 3, 6, 12, 18, 24, 36, 48, and 60 months post-implantation.
Secondary outcome measures1. Absolute weight loss over 60 months, defined simply as the total weight loss for the follow-up period
2. Total change in weight (TWL%) defined as (preoperative (preop) weight – follow up weight)/(preop weight) X 100%, measured at 12, 36 and 60 months
3. Total change in BMI (TBMIL%) defined as (preoperative (preop) BMI – follow up BMI)/(preop BMI) X 100%, measured at 12, 36 and 60 months
4. Plasma glucose levels, HbA1c levels, and resolution of T2DM (% of patients, defined as HbA1C<6) in diabetic patients measured annually over 5 years
Overall study start date01/12/2022
Completion date30/06/2028

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit65 Years
SexBoth
Target number of participants50
Key inclusion criteria1. Age 18 – 65 years
2. Male or female
3. BMI >40 kg/m² and BMI >30 kg/m² with at least one comorbid condition (hypertension [HTN], type 2 diabetes [DT2], sleep apnea)
4. Willingness to comply with the substantial lifelong dietary restrictions required by the procedure (written consent form)
5. History of obesity for at least 5 years
6. History of failure with dieting methods
7. Willingness to follow protocol requirements including signed consent, routine follow-up schedule, completing quality of life (QOL) questionnaires, completing laboratory tests, completing diet and behavior modification counseling
8. Residing within a reasonable distance from an investigating center and able to travel to the investigator to complete all routine follow-up visits
Key exclusion criteria1. Surgery or treatment represents an unreasonable risk to the subject
2. Patient history of inflammatory disease of the gastrointestinal (GI) tract (including ulceration, duodenal ulceration, grade 4 esophagitis, specific inflammation such as Crohn’s disease or ulcerative colitis)
3. Severe cardiopulmonary disease or other serious organic disease
4. Severe coagulopathy, upper gastrointestinal (UGI) bleeding conditions, such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia
5. Congenital or acquired anomalies of the GI
6. Severe hiatal hernia (>3 cm)
7. Pregnant or has the intention of becoming pregnant in the next 12 months
8. Alcohol or drug addiction, active smoker
9. Mental retardation or emotional instability, or psychological characteristics which, in the opinion of the investigators, make the subject a poor candidate for clip surgery
10. Previous esophageal, gastric surgery, hepatectomy, splenectomy
11. Previous endoscopic procedure for obesity
12. Patient under GLP1 medication or weight loss drug
13. Diabetes patient under treatment for gastroparesis
14. Previous bariatric surgery, intestinal obstruction, or adhesive peritonitis
15. Patient history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma, or other autoimmune connective tissue disorder
16. Participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of the Clip clinical trial
Date of first enrolment01/03/2023
Date of final enrolment01/01/2025

Locations

Countries of recruitment

  • Jordan

Study participating centres

Jordan Hospital
Jabal Amman, Queen Nour Street
Amman
11152
Jordan
Al Khalidi Hospital & Medical Center
Jabal Amman, Ibn Khaldoun Street
Amman
11183
Jordan

Sponsor information

Jordan Hospital
Hospital/treatment centre

Gastrointestinal, Bariatric & Metabolic Center
Jabal Amman, Queen Nour Street
Amman
11152
Jordan

Phone +962 (0)6 560 9067
Email info@gbmc-jo.com
Website http://www.jordan-hospital.com/
ROR logo "ROR" https://ror.org/036wxg427

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date01/12/2026
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol file 13/02/2023 No No

Additional files

42966_PROTOCOL.pdf

Editorial Notes

13/02/2023: Trial's existence confirmed by the Institutional Review Boards of Jordan Hospital and Al Khalidi Hospital & Medical Center.